Skip to main content

CareFusion Issues Update on Infant Breathing Product Recall


July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its AirLife™ Infant Breathing Circuit, initiated back in May.
The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units.
The update was posted July 2 on the FDA Website.
On May 29, 2012, CareFusion sent an Urgent Recall Notice to customers and distributors stating that the company had identified potential risks associated with the AirLife Infant Breathing Circuit.
The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to the patient," the letter reads.
To date, there have been no reports of patient harm associated with the affected products, the company says.
There is no change to the remediation plans previously announced by the company. The notification letter contains a complete list of affected product code lot numbers, and asks customers to destroy any affected products remaining in inventory.
The products subject to the recall were manufactured between June 1, 2010, and February 3, 2012.
Since the recall was initiated May 29, 2012, nearly half of the affected customers and distributors have completed the remediation process, the company says.
Questions related to this action should be addressed to CareFusion Customer Service atCustomer.Experience@carefusion.com.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more